Analytical Data
-
基因名
TNFSF8
- Application
-
别名
TNFSF8；CD30L；CD30LG；Tumor necrosis factor ligand superfamily member 8
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P32971
-
表达区间
63-234aa
-
氨基酸序列
QRTDSIPNSPDNVPLKGGNCSEDLLCILKRAPFKKSWAYLQVAKHLNKTKLSWNKDGILHGVRYQDGNLVIQFPGLYFIICQLQFLVQCPNNSVDLKLELLINKHIKKQALVTVCESGMQTKHVYQNLSQFLLDYLQVNTTISVNVDTFQYIDTSTFPLENVLSIFLYSNSD
-
分子量
45.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFSF8, also known as 4-1BB ligand (4-1BBL), is a member of the tumor necrosis factor (TNF) superfamily that plays a crucial role in immune modulation and T cell activation. Its primary function is to enhance T cell proliferation, survival, and cytokine production, making it a key player in adaptive immunity. The expression of TNFSF8 is upregulated in various immune cells, including dendritic cells and activated T cells, and it engages with the 4-1BB receptor (CD137) on T cells to promote immune responses against tumors and infections. Given its significant role in mediating immune responses, TNFSF8 has emerged as a potential target for immunotherapy in cancer treatment, where enhancing T cell activity can lead to improved anti-tumor responses. Research has focused on the production of recombinant TNFSF8 protein to explore its therapeutic potential, investigate its mechanisms of action, and evaluate its effectiveness in combination therapies. Additionally, understanding its interactions and signaling pathways could provide insights into developing novel strategies for modulating immune responses in various diseases, including autoimmune disorders and chronic infections. As the field of immunotherapy continues to evolve, the study of TNFSF8 and its re-engineered forms holds promise for advancing treatment options and improving patient outcomes in cancer and beyond.
